News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Humana reports a higher medical cost ratio and reaffirms, rather than raises, its full-year earnings guidance. Continue Reading
Sharemaestro market context Trend signal active 52 weeks +26.1% · Next-week setup negative 32.8%GE HealthCare Technologies ran at the top of the S&P 500 Wednesday morning, while Humana was among major laggards after both companies posted better-than-expected Q2 earnings signaling a return to profit growth. GEHC broke above its recent trading range that followed its dive on …
Sharemaestro market context Trend signal active 52 weeks +26.1% · Next-week setup negative 32.8%Humana (HUM) reported $40.89 billion in revenue for the quarter ended June 2026, representing a year-over-year increase of 26.2%. EPS of $7.61 for the same period compares to $6.27 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $40.65 billion, …
Sharemaestro market context Trend signal active 52 weeks +26.1% · Next-week setup negative 32.8%Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Humana stock has delivered a powerful run over the past year, yet on the current checks it no longer looks obviously cheap or obviously expensive. …
Sharemaestro market context Trend signal active 52 weeks +26.1% · Next-week setup negative 32.8%Humana, a top-tier medical insurer specializing in Medicare Advantage plans, is expected to have a weak 2026 despite making solid progress early in the year. The company's focus on serving the elderly aligns with US demographic trends and the increasing penetration of Medicare Advantage …
Financial report ©Adobe Stock Images Humana Inc. (NYSE:HUM) shares fell nearly 9% in pre-market trading on Wednesday despite the health insurer reporting second-quarter earnings and revenue that exceeded Wall Street expectations while reaffirming its full-year adjusted earnings guidance. The company posted adjusted earnings of …
Sharemaestro market context Trend signal active 52 weeks +26.1% · Next-week setup negative 32.8%Humacyte, Inc. (HUMA) stock recently closed down 6.44% at $0.63, underperforming the S&P 500. The company's stock has also fallen by 15.62% over the past month, trailing its sector. Investors are looking forward to its upcoming earnings report, with projections of a 58.33% increase …
Humana (NYSE:HUM) Exceeds Q2 CY2026 Expectations Health insurance company Humana (NYSE:HUM) announced better-than-expected revenue in Q2 CY2026, with sales up 26.2% year on year to $40.87 billion. Its non-GAAP profit of $7.61 per share was 8.8% above analysts' consensus estimates. Is now the time …
Sharemaestro market context Trend signal active 52 weeks +26.1% · Next-week setup negative 32.8%Humana (HUM) came out with quarterly earnings of $7.61 per share, beating the Zacks Consensus Estimate of $6.22 per share. This compares to earnings of $6.27 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings …
Sharemaestro market context Trend signal active 52 weeks +26.1% · Next-week setup negative 32.8%Humana cut its full-year earnings outlook on Wednesday as lower Medicare Advantage Star Ratings reduced the quality bonuses it receives from the federal government. The health insurer revised its full-year GAAP earnings target to a minimum of $6.52 per share, compared with its earlier …
Sharemaestro market context Trend signal active 52 weeks +26.1% · Next-week setup negative 32.8%Humana Inc. (NYSE: HUM) has announced the election of Paul Smith and Frederick Crawford to its Board of Directors, effective immediately. Smith, Chief Commercial Officer at Anthropic, PBC, brings over 30 years of experience in enterprise technology go-to-market strategies, while Crawford, former President and …
Investing.com -- Humana Inc. (NYSE: HUM) reported second-quarter earnings before the open on Wednesday, topping consensus expectations. Adjusted earnings per share of $7.61 beat the analyst estimate of $7.23 by $0.38, though shares fell 8.7% premarket following the results. Revenue for the quarter reached …
Sharemaestro market context Trend signal active 52 weeks +26.1% · Next-week setup negative 32.8%Humana, Inc. reported higher second-quarter profit with strong revenue growth but trimmed its fiscal 2026 reported earnings outlook. Despite the cut in the reported EPS view, the company maintained its adjusted earnings and revenue outlook for the fiscal year. Following the announcement, Humana's shares …
Redwood Grove Capital LLC increased its stake in Humana Inc. by 8.7% in the first quarter, making it their 4th largest holding. Other hedge funds also adjusted their positions in the health insurance provider. Humana recently reported strong quarterly earnings, beating analyst expectations, and …
Humana Inc. reported its second-quarter revenue reached $40.87 billion, surpassing FactSet's estimate of $40.57 billion. The company also announced that its Q2 adjusted earnings and revenue rose, and it affirmed its full-year 2026 adjusted EPS outlook of at least $9.00, exceeding FactSet's estimate of …
July 29 (Reuters) - Humana on Wednesday beat Wall Street estimates for second-quarter earnings as the health insurer's spend on medical services was in line with expectations, but it left its annual adjusted profit forecast unchanged. Shares of the company were down about 9% …
Sharemaestro market context Trend signal active 52 weeks +26.1% · Next-week setup negative 32.8%Reports 2Q26 earnings per share (EPS) of $5.73 on a GAAP basis, Adjusted EPS of $7.61; reports year to date (YTD) 2026 EPS of $15.55 on a GAAP basis, $17.91 on an Adjusted basis 2Q26 Insurance segment GAAP benefit ratio of 91.2 percent, in …
Sharemaestro market context Trend signal active 52 weeks +26.1% · Next-week setup negative 32.8%Arrowstreet Capital Limited Partnership increased its stake in Humana Inc. by 26.7% in the first quarter, now owning 235,493 shares valued at $40.83 million. Other hedge funds also adjusted their positions, and institutional investors collectively own 92.38% of the company's stock. Analysts have given …
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Humana (HUM) is back in focus after new research from Humana Healthcare Research on Medicare Advantage selection coincided with rising attention on the company's upcoming …
Sharemaestro market context Trend signal active 52 weeks +26.1% · Next-week setup negative 32.8%Weekly market data show a softer latest week, lighter turnover and mixed confirmation after a sharp medium-term advance.
Humana reports earnings Wednesday after its stock surged this year on improving confidence in Medicare Advantage insurers. Investors will be watching medical costs and the company’s outlook. Continue Reading
Humana Inc. reported strong second-quarter earnings, with net income of $694 million, or $5.73 per share, adjusted to $7.61 per share. These results surpassed Wall Street expectations, which had estimated $6.22 per share. The health insurer also exceeded revenue forecasts, posting $40.87 billion, and …
Humana Inc. (HUM) stock rose 1.98% on Tuesday, ending a four-day losing streak, despite the S&P 500 and Dow Jones Industrial Average also seeing gains. The stock's performance still underperformed compared to its competitors. This market update was automatically generated with data from Dow …
* Humana (HUM [https://seekingalpha.com/symbol/HUM]) is scheduled to announce Q2 earnings results on Wednesday, July 29th, before market open. * The consensus EPS estimate is $7.00 [https://seekingalpha.com/symbol/HUM/earnings/estimates] (+11.6% Y/Y) and the consensus revenue estimate is $40.57B (+25.3% Y/Y). * Over the last 2 years, HUM …
Sharemaestro market context Trend signal active 52 weeks +26.1% · Next-week setup negative 32.8%A new study by Humana Healthcare Research indicates that favorable selection in Medicare Advantage (MA) is substantially lower than previous estimates, potentially leading to a smaller impact on MA payments. The research, published in Health Affairs Scholar, found that using comprehensive encounter data and …
Published in Health Affairs Scholar, the study finds that a single methodological refinement reduces favorable selection estimates by 42%-65%, suggesting a smaller impact on MA payments than previous analyses have indicated LOUISVILLE, Ky., July 28, 2026--(BUSINESS WIRE)--A new study from Humana Healthcare Research (HHR), …
Sharemaestro market context Trend signal active 52 weeks +26.1% · Next-week setup negative 32.8%Wall Street analysts expect Humana (HUM) to post quarterly earnings of $6.22 per share in its upcoming report, which indicates a year-over-year decline of 0.8%. Revenues are expected to be $40.65 billion, up 25.5% from the year-ago quarter. The current level reflects an upward …
Sharemaestro market context Trend signal active 52 weeks +26.1% · Next-week setup negative 32.8%Humana (HUM) Reports Q2: Everything You Need To Know Ahead Of Earnings Health insurance company Humana (NYSE:HUM) will be announcing earnings results this Wednesday before the bell. Here's what you need to know. Humana met analysts' revenue expectations last quarter, reporting revenues of $39.65 …
Sharemaestro market context Trend signal active 52 weeks +26.1% · Next-week setup negative 32.8%This OpenSecrets.org page details the lobbying activities of Humacyte Inc for 2024, identifying seven lobbyists, three of whom are "revolving door" lobbyists with previous federal government experience. The company spent $100,000 on lobbying in 2024, with G2G Consulting employing six lobbyists and DLA Piper …
For Immediate Release Chicago, IL – July 28, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in …
Sharemaestro market context Trend signal active 52 weeks +26.1% · Next-week setup negative 32.8%Humacyte, Inc. (NASDAQ:HUMAW) generated $2.04 million in revenue last year, primarily from its Acellular Human Tissues segment. This represents an increase from $1.56 million in the previous year. The United States was the primary source of this revenue, accounting for the entire $2.04 million.
This article provides an "Institutional Confidence" score for Ihuman Inc (IH) from TradingKey, noting a previous score of 3.00 with no change, updated on July 27, 2026. It lists key institutional shareholders and their recent activity (share holdings and percentage change), highlighting changes such …
This OpenSecrets.org page details the federal agencies that Humana Inc. listed in its lobbying filings for 2024. The healthcare company named 10 different federal entities, including both executive branches like the Centers for Medicare & Medicaid Services and legislative bodies such as the U.S. …
This article focuses on the cash flow from operating activities of Humana Inc. (HAM:HUM), listed on the Hamburg Stock Exchange. It indicates that the market is currently closed with no trades. The information is presented within the financial section of a trading platform, suggesting …
Search by ticker symbol or company name and select a result to open its chart.